M2 PRESSWIRE-August 30, 2019-:
Ursodeoxycholic Acid Market To Be Driven By Changing Demand From Patients and Developments Occurring Worldwide Till 2022 | Million Insights
Six hundred five women were randomly assigned to either
ursodeoxycholic acid or placebo (305 and 300, respectively) given as two oral tablets a day at an equivalent dose of 500 mg twice a day.
In a paper published in the journal 'The Lancet', it was found that 605 pregnant women with intrahepatic cholestasis of pregnancy (ICP) were recruited with half receiving
ursodeoxycholic acid (known as 'urso'), the current drug used to treat the condition, and half a placebo.
Bile salts may also be sulfated or glucuronidated or--in the case of
ursodeoxycholic acid (UDCA)--undergo N-acetylglucosamination.
Eligible PBC patients with either an inadequate response, defined as alkaline phosphatase greater than 1.67 times the upper limit of normal, or intolerance to
ursodeoxycholic acid ere randomized to daily seladelpar at 5 or 10 mg.
The 24-week placebo-controlled trial is being held across multiple countries in 111 primary biliary cholangitis patients having inadequate response to
ursodeoxycholic acid. The primary efficacy endpoint of the mid-stage trial is change in gamma glutamyl transpeptidase (GGT) at week 24.
Several agents, including
ursodeoxycholic acid (UDCA), omega-3 fatty acids, black seed oil, virgin coconut oil, and vitamin E, are used to prevent chemotherapy-induced liver damage (5-9).
CDCA is also the precursor of
ursodeoxycholic acid (UDCA) which is another effective drug for gallstone treatment [3, 4].
Currently, first-line treatment includes
ursodeoxycholic acid in patients with ABCB4 deficiency (PFIC3) and partial biliary diversion in patients with ATP8B1 or ABCB11 deficiency (PFIC1 and PFIC2).